Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 3/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.30 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4536724 | 0.81 | DRD1 (0.39) | DRD1HCRTR1HCRTR2GAAALDH1A1 | |
| SCHEMBL24133692 | 0.81 | DRD1 (0.39) | DRD1GAAPIK3CAALDH1A1L3MBTL1 | |
| SCHEMBL30345266 | 0.81 | DRD1 (0.39) | DRD1GAAPIK3CAALDH1A1L3MBTL1 | |
| SCHEMBL15719149 | 0.79 | FDPS (0.40) | KDM4ESRCGAAPIK3CAALDH1A1 | |
| SCHEMBL29953000 | 0.77 | ALDH1A1 (0.41) | KDM4ESRCGAAALDH1A1L3MBTL1 | |
| SCHEMBL17248014 | 0.77 | NOS3 (0.42) | HCRTR1HCRTR2GAAPIK3CATRPV4 | |
| SCHEMBL28923138 | 0.76 | SRC (0.35) | KDM4ESRCPIK3CAALDH1A1ALDH1A3 | |
| SCHEMBL16762140 | 0.75 | PTGS2 (0.39) | KDM4ESRCALDH1A1L3MBTL1 | |
| SCHEMBL21585391 | 0.75 | AGBL2 (0.39) | DRD1HCRTR1HCRTR2GAAPIK3CA | |
| SCHEMBL4540518 | 0.75 | HCRTR1 (0.42) | DRD1HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242970-B2 | Lactam derivatives useful as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-01-26 | — | — | US | disclosed |
| EP-2638008-B1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-07-01 | — | — | EP | disclosed |
| EP-2638008-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-12 | — | — | US | disclosed |
| WO-2012063207-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | DRD1 274/4885HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.